Alida Biosciences

Alida Biosciences is an early-stage biotech company pioneering tools for epitranscriptomics, the study of RNA modifications. Its core technology, the EpiPlex™ platform, employs proximity barcoding and engineered protein binders to convert sequencing-silent RNA modifications into readable barcodes, enabling multi-target detection from standard short-read RNA-seq data. The company is positioning its platform to serve basic research, biomarker discovery, and drug development, particularly in oncology, neurology, and immunology, as evidenced by a recent strategic collaboration with STORM Therapeutics. AlidaBio operates as a private, pre-revenue platform company targeting the growing market for RNA analysis tools.

EpiPlex™ platform using proximity barcoding with engineered protein binders to convert sequencing-silent RNA modifications into NGS-readable DNA barcodes, enabling multi-target detection from standard short-read RNA-seq data. Complemented by EpiScout™ machine-learning analysis software.

AlidaBio competes in the niche but growing epitranscriptomics tools market. Competitors include companies offering antibody-based enrichment kits (e.g., for m6A IP), providers of direct RNA sequencing technologies (e.g., Oxford Nanopore), and academic methods. Its key differentiation is the ability to multiplex modifications from standard short-read sequencers.